John Wyatt

John Wyatt is a seasoned professional in the life sciences and genomics sectors, currently serving as a Population Health and Genomics Sector Liaison at Illumina since June 2018, and concurrently as the UK Genomics Funding Liaison. With a focus on business development and prospective health initiatives, Wyatt has actively contributed to significant projects such as the UK Biobank and the globally largest prospective health initiative, Our Future Health, where Illumina is represented on the Founders Board. Prior experience includes founding B2B Performance, managerial roles at Leica Biosystems and Aperio, and pivotal positions in business development at i3 Pharmaceutical Services and Paracel. Wyatt holds a Ph.D. in Chemistry from the University of Bath and an MBA in Business Strategy from The Open University.